Oct 30, 2019 4:05 pm EDT Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019
Sep 09, 2019 8:00 am EDT Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
Aug 08, 2019 7:30 am EDT Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress
Aug 01, 2019 4:00 pm EDT Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019
Jul 16, 2019 7:00 am EDT Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year
Jun 29, 2019 7:00 am EDT Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)